Study Estimates Health Risks for Women Exposed to DES In Utero
Up until 1971, doctors in the United States prescribed a drug called diethylstilbestrol (DES) to millions of healthy pregnant women. The daughters of these women, who were exposed to the drug in utero, are at an increased risk of developing a range of adverse health effects related to the exposure. A study in the October 6 New England Journal of Medicine estimates the absolute risks of these health effects and summarizes decades of research on so-called DES daughters. For more information, see NCI's press release.
A combination of two available cancer drugs could offer a new treatment option for postmenopausal women whose advanced breast cancer has stopped responding to hormonal therapy, researchers said last week at a scientific meeting in Stockholm, Sweden.
Read more > >
Just as researchers and clinicians have begun to better understand that cancer is a highly complex group of diseases and have adjusted how they study and treat these diseases, cancer advocates have realized that effective advocacy is a complex and multidimensional pursuit—one in which they can play many roles. Read more > >
A breast cancer survivor and cancer research advocate explains why she turned to advocacy and describes her experience as the lead advocate on one national study. Read more > >
- Bone Density Drug Approved for Prostate and Breast Cancer Patients
- NIH's Intramural Research Program Unveils New Website
- Congressional Members and Staff Turn to NCI for Cancer Research Information
- Congressional Appropriations Committees Put Forward Labor-HHS Bills
- NCI Updates Online Dietary Recall Tool
- Rudolf Jaenisch Receives National Medal of Science
- NCI's James Gulley Wins Presidential Early Career Award for Scientists and Engineers
- New National Cancer Advisory Board Member Named
- Cyber-Seminar Will Address Cancer Control and Prevention for Latino Populations
- Small Businesses: Apply for Cancer Research Funding by November 7
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.org.